Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285823 | 0.89 | PTGS2 (0.39) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL5313412 | 0.86 | MAPK8 (0.37) | SMN1; SMN2PTGS2TP53ALDH1A1MAPK8 | |
| SCHEMBL4576546 | 0.85 | PTGS2 (0.49) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL13325145 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL3288851 | 0.81 | PTGS2 (0.45) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL3286763 | 0.81 | PTGS2 (0.42) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL3285310 | 0.79 | PTGS2 (0.43) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL3285785 | 0.79 | PTGS2 (0.41) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL3288330 | 0.77 | PTGS2 (0.40) | SMN1; SMN2PTGS2LMNAMEN1KMT2A | |
| SCHEMBL3287843 | 0.77 | PTGS2 (0.40) | PTGS2LMNAMEN1KMT2ATMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | claimed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1761531-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006001750-A1 | IMIDAZOLE VARIANTS AS MODULATORS OF GABA RECEPTOR FOR THE TREATMENT OF GI DISORDERS | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | SMN1; SMN2 1857/4885PTGS2 405/4885LMNA 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.